Literature DB >> 16855275

Will kinase inhibitors have a dark side?

Charles L Sawyers1.   

Abstract

Mesh：

Substances：

Year:  2006        PMID： 16855275     DOI： 10.1056/NEJMcibr062354

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  12 in total

1.  Phase I pharmacokinetic and pharmacodynamic study of triciribine phosphate monohydrate, a small-molecule inhibitor of AKT phosphorylation, in adult subjects with solid tumors containing activated AKT.

Authors:  Christopher R Garrett; Domenico Coppola; Robert M Wenham; Christopher L Cubitt; Anthony M Neuger; Timothy J Frost; Richard M Lush; Daniel M Sullivan; Jin Q Cheng; Saïd M Sebti
Journal:  Invest New Drugs       Date:  2010-07-20       Impact factor: 3.850

2.  Asymmetric cancer cell division regulated by AKT.

Authors:  Ipsita Dey-Guha; Anita Wolfer; Albert C Yeh; John G Albeck; Revati Darp; Eduardo Leon; Julia Wulfkuhle; Emanuel F Petricoin; Ben S Wittner; Sridhar Ramaswamy
Journal:  Proc Natl Acad Sci U S A       Date:  2011-07-14       Impact factor: 11.205

3.  Molecular imaging of phosphorylation events for drug development.

Authors:  C T Chan; R Paulmurugan; R E Reeves; D Solow-Cordero; S S Gambhir
Journal:  Mol Imaging Biol       Date:  2008-12-02       Impact factor: 3.488

4.  The actin-bundling protein palladin is an Akt1-specific substrate that regulates breast cancer cell migration.

Authors:  Y Rebecca Chin; Alex Toker
Journal:  Mol Cell       Date:  2010-05-14       Impact factor: 17.970

5.  Regulation of the metastasis suppressor gene MKK4 in ovarian cancer.

Authors:  Monique A Spillman; Judith Lacy; Susan K Murphy; Regina S Whitaker; Lisa Grace; Vanessa Teaberry; Jeffrey R Marks; Andrew Berchuck
Journal:  Gynecol Oncol       Date:  2007-02-05       Impact factor: 5.482

Review 6.  Signaling pathways in the epithelial origins of pulmonary fibrosis.

Authors:  William D Hardie; James S Hagood; Vrushank Dave; Anne-Karina T Perl; Jeffrey A Whitsett; Thomas R Korfhagen; Stephan Glasser
Journal:  Cell Cycle       Date:  2010-07-03       Impact factor: 4.534

Review 7.  Emerging concepts in the pathogenesis of lung fibrosis.

Authors:  William D Hardie; Stephan W Glasser; James S Hagood
Journal:  Am J Pathol       Date:  2009-06-04       Impact factor: 4.307

Review 8.  Targeted therapies for malignant glioma: progress and potential.

Authors:  Ronald W Mercer; Matthew A Tyler; Ilya V Ulasov; Maciej S Lesniak
Journal:  BioDrugs       Date:  2009       Impact factor: 5.807

9.  Inhibition of PI3K by PX-866 prevents transforming growth factor-alpha-induced pulmonary fibrosis.

Authors:  Timothy D Le Cras; Thomas R Korfhagen; Cynthia Davidson; Stephanie Schmidt; Matthew Fenchel; Machiko Ikegami; Jeffrey A Whitsett; William D Hardie
Journal:  Am J Pathol       Date:  2009-12-30       Impact factor: 4.307

10.  Current available therapies and future directions in the treatment of malignant gliomas.

Authors:  Annick Desjardins; David A Reardon; James J Vredenburgh
Journal:  Biologics       Date:  2009-07-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.